153 related articles for article (PubMed ID: 11854548)
21. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
[TBL] [Abstract][Full Text] [Related]
22. Hypersensitivity reactions associated with 5- hydroxytryptamine(3)-receptor antagonists: a class effect?
Kataja V; de Bruijn KM
Lancet; 1996 Mar; 347(9001):584-5. PubMed ID: 8596322
[TBL] [Abstract][Full Text] [Related]
23. Granisetron. An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy.
Yarker YE; McTavish D
Drugs; 1994 Nov; 48(5):761-93. PubMed ID: 7530631
[TBL] [Abstract][Full Text] [Related]
24. [Medical treatment of chemotherapy-induced nausea and vomiting].
Herrstedt J
Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy.
Anastasia PJ
Oncol Nurs Forum; 2000 Apr; 27(3):483-93. PubMed ID: 10785902
[TBL] [Abstract][Full Text] [Related]
26. Nurses' perceptions of antiemetic effectiveness.
Rhodes VA; McDaniel RW; Simms SG; Johnson M
Oncol Nurs Forum; 1995 Sep; 22(8):1243-52. PubMed ID: 8532549
[TBL] [Abstract][Full Text] [Related]
27. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
28. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
29. Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability.
Prentice HG
Support Care Cancer; 2003 Aug; 11(8):501-8. PubMed ID: 12845514
[TBL] [Abstract][Full Text] [Related]
30. Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
Tricco AC; Soobiah C; Hui W; Antony J; Struchkov V; Hutton B; Hemmelgarn B; Moher D; Straus SE
BMC Pharmacol Toxicol; 2015 Jan; 16():1. PubMed ID: 25623303
[TBL] [Abstract][Full Text] [Related]
31. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile.
Goodin S; Cunningham R
Oncologist; 2002; 7(5):424-36. PubMed ID: 12401905
[TBL] [Abstract][Full Text] [Related]
32. Re: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Aapro M; Rabaeus M
Am J Clin Oncol; 2005 Dec; 28(6):634-5. PubMed ID: 16317278
[No Abstract] [Full Text] [Related]
33. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
34. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
35. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
[TBL] [Abstract][Full Text] [Related]
36. Optimal selection of antiemetics in children receiving cancer chemotherapy.
Roila F; Aapro M; Stewart A
Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
[TBL] [Abstract][Full Text] [Related]
37. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
[TBL] [Abstract][Full Text] [Related]
38. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
Carmichael J; Harris AL
Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
[TBL] [Abstract][Full Text] [Related]
39. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
40. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]